Ballicules.com

Carteolol

OCUPRESS

Carteolol ballicule: receptor binding, kinetics and half-life diagram
Mechanism of action: Carteolol ballicule

What it isNon-selective beta blocker eye drop with intrinsic sympathomimetic activity; glaucoma.

Why this onePartial agonism gives a slightly better lipid and heart-rate profile than timolol.

What limits itSystemic beta blockade still occurs. Avoid in asthma and heart block.

Carteolol molecular structure (skeletal formula)
Molecular structure: Carteolol

Carteolol prescription history

Animated chart of estimated U.S. prescriptions per year, Glaucoma medicines (1900–2026). Carteolol enters in 1992 (estimated).

FDA-approved for

Principal riskSystemic beta blockade from eye drops

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger3 / 4
Weight-gain liability1 / 4
Sedation liability1 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityBradycardia, hypotension and bronchospasm; overdose may cause conduction block or cardiogenic shock.

FDA label

NO BOXED WARNINGS

FDA dosingPopulationStartTargetMax
Elevated intraocular pressure / open-angle glaucomaAdults1 drop affected eye(s) BID1 drop BID

Renal Undefined

Hepatic Undefined

Instructions

Available strengths

Contraindications

Cautions

Adverse reactions

Pregnancy Undefined

Lactation Undefined

Cost

Carteolol (OCUPRESS)
Strength#/mogeneric $/unitCostPlus
1 %dropsper unitnot offered
NADAC is a voluntary CMS survey of what retail community pharmacies pay for the drugs they stock. Carteolol is dispensed outside retail pharmacies, so it rarely appears on surveyed invoices.

Generic entry2000

Open Carteolol in the interactive console ↗

Self-check